Home > Boards > Free Zone > Health and Sciences > Biotech Values

AGN is sharply down on the failure to

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 739
Posts 112,735
Boards Moderated 17
Alias Born 09/05/02
160x600 placeholder
DewDiligence Member Level  Tuesday, 10/30/18 02:45:55 PM
Re: dewophile post# 221765
Post # of 232864 
AGN is sharply down on the failure to reduce debt by selling either of the two business units slated for divestiture:

https://finance.yahoo.com/news/botox-sales-power-allergans-profit-beat-forecast-raise-122924148--finance.html
Quote:
Allergan has been shopping its women's health and infectious disease businesses since May, following a strategic review of the company undertaken in an effort to reverse a steep slide in its share price.

On call with analysts to discuss third quarter results, Chief Executive Officer Brent Saunders said early buyer interest for the units was below the price he believes they are worth.

"These are good businesses, right? We have always said that while we absolutely would like to sell these businesses, we need to make sure that we get the right price given the dilutive effect on a variety of our financial metrics," Saunders said.



“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist